Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas

Journal of Pathology

Volumn 229, Issue 1, 2013, Pages 111-120

  Anglesio, Michael S ^a   Kommoss, Stefan ^a   Tolcher, Mary C ^b   Clarke, Blaise ^c   Galletta, Laura ^d   Porter, Henry ^a   Damaraju, Sambasivarao ^e   Fereday, Sian ^d   Winterhoff, Boris J ^b   Kalloger, Steve E ^f   Senz, Janine ^a   Yang, Winnie ^g   Steed, Helen ^e   Allo, Ghassan ^c   Ferguson, Sarah ^h   Shaw, Patricia ⁱ   Teoman, Attila ^b   Garcia, Joaquin J ^b   Schoolmeester, John K ^b   Bakkum Gamez, Jamie ^b   Tinker, Anna V ^g   Bowtell, David D ^d,j   Huntsman, David G ^a,g   Gilks, C Blake ^a,f   McAlpine, Jessica N ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF ALBERTA   (Canada)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

^j UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

HER2; heterogeneity; KRAS; mutation; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHROMOGENIC SILVER IN SITU HYBRIDIZATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MUCINOUS BORDERLINE OVARIAN TUMOR; MUCINOUS OVARIAN CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN TARGETING;

ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CANADA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; YOUNG ADULT;

EID: 84872862768     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4088     Document Type: Article

References (55)

1. Gilks CB,. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004; 23: 200-205.
2. Seidman JD, Kurman RJ, Ronnett BM,. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27: 985-993.
3. Vang R, Gown AM, Wu LS, et al,. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006; 19: 1421-1428.
4. Yemelyanova AV, Vang R, Judson K, et al,. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 2008; 32: 128-138.
5. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
6. Gilks CB, Ionescu DN, Kalloger SE, et al,. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008; 39: 1239-1251.
7. Hess V, A'Hern R, Nasiri N, et al,. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044.
8. Mackay HJ, Brady MF, Oza AM, et al,. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-952.
9. Pectasides D, Fountzilas G, Aravantinos G, et al,. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005; 97: 436-441.
10. Tabrizi AD, Kalloger SE, Kobel M, et al,. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 2010; 29: 99-107.
11. Pignata S, Ferrandina G, Scarfone G, et al,. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer 2008; 8: 252.
12. Matsuo K, Nishimura M, Bottsford-Miller JN, et al,. Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res 2011; 17: 5367-5378.
13. Sugiyama T, Kumagai S, Hatayama S. [Treatments of epithelial ovarian cancer by histologic subtype]. Gan To Kagaku Ryoho 2009; 36: 187-192.
14. Sato S, Itamochi H, Kigawa J, et al,. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci 2009; 100: 546-551.
15. Fountain J, Trimble E, Birrer MJ,. Summary and discussion of session recommendations. Gynecol Oncol 2006; 103: S23-S25.
16. Vereczkey I, Serester O, Dobos J, et al,. Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res 2011; 17: 551-559.
17. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-931.
18. Kalloger SE, Kobel M, Leung S, et al,. Calculator for ovarian carcinoma subtype prediction. Mod Pathol 2011; 24: 512-521.
19. Cho H, Lim BJ, Kang ES, et al,. Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. Tohoku J Exp Med 2009; 218: 129-139.
20. McAlpine JN, Wiegand KC, Vang R, et al,. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009; 9: 433.
21. Wolff AC, Hammond ME, Schwartz JN, et al,. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
22. Wolff AC, Hammond ME, Schwartz JN, et al,. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
23. Anglesio MS, Arnold JM, George J, et al,. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008; 6: 1678-1690.
24. Tapia C, Glatz K, Novotny H, et al,. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 2007; 20: 192-198.
25. Matsui Y, Inomata M, Tojigamori M, et al,. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005; 27: 681-685.
26. Farley J, Fuchiuji S, Darcy KM, et al,. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol 2009; 113: 341-347.
27. Bookman MA, Darcy KM, Clarke-Pearson D, et al,. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-290.
28. Wu Y, Soslow RA, Marshall DS, et al,. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 2004; 95: 570-575.
29. Steffensen KD, Waldstrom M, Jeppesen U, et al,. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17: 798-807.
30. Lin WL, Kuo WH, Chen FL, et al,. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Ann Surg Oncol 2011; 18: 2388-2394.
31. Wong KK, Tsang YT, Deavers MT, et al,. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010; 177: 1611-1617.
32. Papouchado BG, Myles J, Lloyd RV, et al,. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010; 34: 767-776.
33. Penault-Llorca F, Bilous M, Dowsett M, et al,. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 2009; 132: 539-548.
34. Kunz PL, Mojtahed A, Fisher GA, et al,. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012; 20: 13-24.
35. Hofmann M, Stoss O, Shi D, et al,. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
36. Garcia I, Vizoso F, Martin A, et al,. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003; 10: 234-241.
37. Tung KH, Goodman MT, Wu AH, et al,. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003; 158: 629-638.
38. Seidman JD, Horkayne-Szakaly I, Haiba M, et al,. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23: 41-44.
39. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 2011; 205: 480.e1-480.e8.
40. Tan SB, Dear KB, Bruzzi P, et al,. Strategy for randomised clinical trials in rare cancers. BMJ 2003; 327: 47-49.
41. Lilford RJ, Thornton JG, Braunholtz D,. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995; 311: 1621-1625.
42. Lièvre A, Blons H, Laurent-Puig P,. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010; 29: 3033-3043.
43. Laurent-Puig P, Cayre A, Manceau G, et al,. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930.
44. Pallis A, Briasoulis E, Linardou H, et al,. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Curr Med Chem 2011; 18: 1613-1628.
45. Linardou H, Briasoulis E, Dahabreh IJ, et al,. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 2011; 37: 221-233.
46. Dahabreh IJ, Terasawa T, Castaldi PJ, et al,. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154: 37-49.
47. Bronte G, Rizzo S, La Paglia L, et al,. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010; 36 (Suppl 3): S21-S29.
48. Rizzo S, Bronte G, Fanale D, et al,. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 2010; 36 (Suppl 3): S56-S61.
49. Russo A, Rizzo S, Bronte G, et al,. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2009; 77 (Suppl 1): 57-68.
50. Chung KY, Shia J, Kemeny NE, et al,. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
51. Harrison ML, Jameson C, Gore ME,. Mucinous ovarian cancer. Int J Gynecol Cancer 2008; 18: 209-214.
52. Lee KR, Scully RE,. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 2000; 24: 1447-1464.
53. Vang R, Gown AM, Barry TS, et al,. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006; 30: 1130-1139.
54. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al,. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 2008; 3: 41.
55. Kobel M, Kalloger SE, Santos JL, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 116: 50-56.